Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection. Globally, the number of annual deaths caused due to HIV/AIDS declined from 2.3 million in 2005 to 1.5 million in 2013, according to a report on AIDS published by the UN. For the treatment of AIDS/HIV, anti-retroviral therapy (ART) is used, which is a combination of medicines that have proved to be effective for years. Anti-retroviral therapy prevents the multiplication of human immunodeficiency virus, and thereby, reduces virus in the patient’s body, protecting the immune system. HIV regimen initially includes three anti-retroviral drugs from at least two different drug classes.
If employed on time, anti-retroviral therapy prevents HIV infection from culminating into AIDS; the therapy increases the lifespan of the patient and also significantly reduces the risk of transmission of the virus. Pharmaceutical companies are focusing on research and development of novel drugs that can prove to be a long-term cure for HIV virus and can forever suppress the virus throughout the life of an individual. Thus, anticipated approval of several new drugs for treatment of AIDS in the near future is poised to propel the growth of the acquired immunodeficiency syndrome treatment market during the forecast years.
The acquired immunodeficiency syndrome treatment market can be segmented based on drug class, distribution channel, and region, as shown in the following:
Acquired Immunodeficiency Syndrome (AIDS) Market, by Drug Class:
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Abacavir (ABC)
- Didanosine (ddI)
- Zidovudine or azidothymidine (ZDV or AZT)
- Emtricitabine (FTC)
- Others (Stavudine (d4T), etc.)
- Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Efavirenz (EFZ)
- Etravirine (ETR)
- Nevirapine (NVP)
- Othets (rilpivirine (RPV), etc.)
Acquired Immunodeficiency Syndrome (AIDS) Treatment Market, by Distribution Channel Class:
The acquired immunodeficiency syndrome treatment market can be divided into drug therapy, gene therapy, cell therapy, and others. Based on disease indication, the acquired immunodeficiency syndrome treatment market can be categorized into genetic disorders, rare cancer, rare blood disorders, autoimmune disorders, infectious diseases, and others. In terms of region, the acquired immunodeficiency syndrome treatment market can be classified into Asia Pacific (APAC), Europe, Middle East & Africa (MEA), North America (NA), and Latin America (LA).
Key players in the acquired immunodeficiency syndrome treatment market are Shire Plc., AstraZeneca Eli Lilly and Company, Merck KGaA, Sanofi, Pfizer, Inc., Amgen Inc., Biogen Inc., Novartis AG, Actelion Ltd, Daiichi Sankyo Company, etc. Intense competition is driving acquisitions and in-licensing agreements as companies are striving to expand and diversify their product pipeline. For instance, Shire Plc., acquired Dyax Corp in 2015 in order to expand the former’s product offerings for acquired immunodeficiency syndrome treatment. Strategic partnerships and alliances are common as companies are aiming to synergize their programs and develop combination acquired immunodeficiency syndrome therapies.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.